ArticleScientific reports2025
Pythium insidiosum-antigen enhances neutrophil-mediated killing of zoospores.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pythium insidiosum-antigen (PIA) immunotherapy has been used to treat human pythiosis. This study compared PIA-stimulated and unstimulated neutrophils on zoospore viability of P. insidiosum strains. We cultured and collected zoospores of 6 P. insidiosum strains, CBS 777.84, ATCC 58643, ATCC 90586, PEC1, PC10, and CBS 101039. PIA concentrations of 0.01, 0.1, 1, and 10 µg/ml were prepared and were used to stimulate neutrophils isolated from healthy volunteers. The MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay was used to calculate the zoospore viability of P. insidiosum strains. Neutrophils stimulated with 0.01 or 0.1 µg/ml PIA, or both, showed a significant reduction in the viability of zoospores of CBS 777.84, ATCC 58643, CBS 101039, PC10, and PEC1 strains. Furthermore, 1 µg/ml PIA-induced neutrophils elicited a significant decrease in the viability of zoospores of ATCC 58643, CBS 101039, and PC10 strains. However, a higher dose of PIA (10 µg/ml) did not demonstrate superiority in reducing the zoospore viability of all six strains. Our findings suggest that PIA immunotherapy improves the zoospore-killing activity of neutrophils, and neutrophils might be involved in the forefront mechanism responsible for the beneficial effects of PIA immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.